Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients

Figure 1 Response rates to ruxolitinib. A: Overall response rates (n = 10) and response rates of the skin (n = 5), digestive tract (n = 6), and liver (n = 2) to ruxolitinib in patients with acute graft-vs-host disease; B: Overall response rates (n = 28) and response rates of the oral cavity (n = 11), skin (n = 21), liver (n = 4), eye (n = 12), lungs (n = 8), fascia (n = 10), and digestive tract (n = 6) to ruxolitinib in patients with chronic graft-vs-host disease. CR: Complete response; PR: Partial response.